Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Centene (CNC) vs Molina Healthcare (MOH): Weighing the Stronger Setup in Managed Care

Centene (CNC) vs Molina Healthcare (MOH): Weighing the Stronger Setup in Managed Care

Key Takeaways

  • CNC and MOH are both government-sponsored managed care organizations, but Centene is the far larger player with a market capitalization roughly three times that of Molina.
  • Centene has delivered stronger recent relative performance, more than doubling off its 52-week low, while Molina's recovery has been more volatile after a sharp fourth-quarter 2025 setback.
  • Analyst positioning favors Centene, which carries a consensus Buy rating, compared with a predominantly Hold consensus for Molina.
  • Tickeron AI Verdict: CNC — the AI favors Centene on trend consistency, scale, and more stable earnings momentum.
  • For more detail on each name, visit the CNC Major News and CNC Today's Price Move pages, or the MOH Major News and MOH Today's Price Move pages.

Context for the Comparison

Centene Corporation (CNC) and Molina Healthcare (MOH) operate at the heart of the managed care sector. Both companies focus heavily on Medicaid and other government-funded programs, so their results move in tandem with policy changes, reimbursement rates, and medical-cost trends. A direct comparison helps clarify how two similar business models are positioned differently in the current environment.

Centene's Scale and Recent Momentum

Centene stands as the largest Medicaid managed care organization in the United States, with additional exposure to Medicare, commercial lines, and pharmacy services. The stock has rallied sharply in recent weeks after the midterm elections, reflecting greater investor certainty around Medicaid and Affordable Care Act funding. Shares have more than doubled from the 52-week low near $31 and now sit close to multi-year highs.

Fundamentals support the move. Centene posted better-than-expected third-quarter results with adjusted EPS above consensus and raised full-year guidance. The health benefits ratio has improved, prompting several analysts to lift price targets. A broad consensus Buy rating backs the sentiment. On the other side, a Department of Justice matter tied to a whistleblower lawsuit and ongoing exposure to medical-cost trends remain points to watch. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock’s momentum stacks up against peers.

Molina's Recovery Path and Challenges

Molina Healthcare concentrates on Medicaid, Medicare, and Marketplace coverage for lower-income populations, with Medicaid representing the bulk of premium revenue. After a sharp drop in early February 2026 following a fourth-quarter 2025 loss, the stock has climbed roughly 70% from its February low. A first-quarter profit beat and solid third-quarter results helped the rebound.

In the latest quarter, Molina beat both revenue and adjusted EPS forecasts while reaffirming full-year guidance of at least $5.25 per share. Management views current Medicaid margins as a likely trough and outlined early 2027 EPS building blocks above $9.50. Membership has contracted about 6% year over year due to redeterminations and work requirements, and the company is exiting its underperforming Medicare Advantage Prescription Drug line while reducing its Marketplace presence. These shifts introduce near-term volatility.

Side-by-Side Assessment

Scale sets the two apart most clearly. Centene’s market capitalization is about three times larger, and its revenue base offers broader diversification across Medicaid, Medicare, and commercial segments. Molina remains more concentrated in Medicaid, where individual contracts and rate decisions carry greater weight.

Momentum patterns also diverge. Centene’s gains have been steadier, supported by the Buy consensus and rising targets. Molina’s advance has been strong yet more uneven, resting on expectations of margin recovery rather than immediate earnings growth. Risk profiles differ too: Centene contends with regulatory scrutiny and elevated medical costs, while Molina faces membership attrition and contract transitions. Valuation-wise, Centene trades at a modest forward multiple with improving margins; Molina’s trailing P/E is not meaningful after its recent loss, so investors are effectively pricing in a 2027 recovery that has yet to appear in results.

Where the AI Lens Points

Based on the observable factors, Tickeron’s AI would likely rank CNC ahead of MOH right now. Centene shows more consistent relative performance, steadier earnings momentum, and greater resilience from its size and diversification. Molina’s margin-trough narrative is intriguing but hinges on forward assumptions not yet validated in reported numbers. On trend consistency and market positioning, Centene currently looks like the more probable setup.

Using AI Tools in Portfolio Work

When evaluating names like these, I often review Tickeron’s Trending AI Robots to see how automated strategies are positioned across the broader market. The page surfaces bots with timely setups and performance records, offering a useful data-driven layer alongside traditional analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MOH, CNC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


MOH in upward trend: 10-day moving average moved above 50-day moving average on October 15, 2026

The 10-day moving average for MOH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 52 cases where MOH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on MOH as a result. In 57 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

MOH moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in 215 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 148 of 222 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Bearish Trend Analysis

The 10-day RSI Indicator for MOH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.

The Moving Average Convergence Divergence Histogram (MACD) for MOH turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 32 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

MOH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. MOH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.616) is normal, around the industry mean (3.520). MOH's P/E Ratio (1306.188) is considerably higher than the industry average of (126.353). Projected Growth (PEG Ratio) (0.880) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.233) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 16%. CVS experienced the highest price growth at 7%, while MOH experienced the biggest fall at 0%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was -43%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 43
Price Growth Rating: 37
SMR Rating: 72
Profit Risk Rating: 83
Seasonality Score: -6 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of health care services to persons eligible for Medicaid

Industry ManagedHealthCare

Industry
Managed Health Care
Address
200 Oceangate
Phone
+1 562 435-3666
Employees
19000
Web
https://www.molinahealthcare.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.